Emergence of SARS-CoV-2 variant B.1.575.2 containing the E484K mutation in the spike protein in Pamplona (Spain) May-June 2021

Running title: Emergence of B.1.575.2 SARS-CoV-2 lineage in Pamplona (Spain)

Camino Trobajo-Sanmartín^{1,2*}, Ana Miqueleiz^{1,2}, María Eugenia Portillo^{1,2}, Miguel Fernández-Huerta^{1,2}, Ana Navascués^{1,2}, Pilar Sola Sara³, Paula López Moreno³, Gonzalo R Ordoñez⁴, Jesús Castilla^{2,5,6}, Carmen Ezpeleta^{1,2}

¹ Departament of Clinical Microbiology, Complejo Hospitalario de Navarra. Pamplona, Spain.

² Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

³ Servicio de Urgencias Extrahospitalarias (SUE), Pamplona, Spain

⁴ Centro de Secuenciación NASERTIC, Pamplona, Spain.

⁵ Instituto de Salud Pública de Navarra, Pamplona, Spain.

⁶ CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

*Corresponding author: Camino Trobajo-Sanmartín

Email: camino.trobajo.sanmartin@navarra.es

Keywords: SARS-CoV-2, E484K mutation, lineage B.1.575, variant, sequencing

Abstract

With the emergence of new SARS-CoV-2 variants and the acquisition of novel mutations in exiting lineages, the need to implement methods capable of monitoring viral dynamics arises. We report the emergence and spread of a new SARS-CoV-2 variant within B.1.575 lineage containing the E484K mutation in the spike protein (named B.1.575.2) in a region of Northern Spain between May and June 2021. SARS-CoV-2 positive samples with cycle threshold value less than or equal to 30 were selected to screen of presumptive variants using the TaqPath™ COVID-19 RT-PCR kit and TaqMan™ SARS-CoV-2 Mutation Panel. Confirmation of variants was performed by whole genome sequencing. Of the 200 samples belonging to the B.1.575 lineage, 194 (97%) corresponded to the B.1.575.2 sub-lineage, which was related to the presence of the E484K mutation. Of 197 cases registered in GISAID EpiCoV database as lineage B.1.575.2 194 (99.5%) were identified in Pamplona (Spain). This report emphasizes the importance of complementing surveillance of SARS-CoV-2 with sequencing for the rapid control of emerging viral variants.

Introduction

During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several variants were catalogued as variants of concern (VOC) and variants of interest (VOI) by the European Centre for Disease Prevention and Control has emerged in different countries. As of June 23, 2021, the four important lineages with evidenced impact on transmissibility, severity and immunity are lineage B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and P.1 (Gamma) (1-4). Lineages B.1.351 and P.1 were of specific concern because they present the spike mutation E484K, which has been associated with the reduced neutralizing activity of antibodies and may be associated

with the reduced efficacy of the vaccine (2,3,5,6). Initially, the B.1.1.7 lineage had mutations N501Y and D614G and the characteristic Δ H69/ Δ V70 deletion in the spike protein; however, in early 2021, Public Health England reported the first B.1.1.7 SARS-CoV-2 cases that had acquired the E484K mutation (3,7).

In this regard, concerns about the emergence of new SARS-CoV-2 variants and the acquisition of new mutations in existing lineages, such as the accumulation of mutations in the spike gene in B.1.1.7, have been developing since the onset of the pandemic. This study identified the emergence and spread of the E484K spike mutation within the SARS-CoV-2 B.1.575 lineage that has increased in the circulating virus population in Pamplona (Spain) between May and June 2021. Additionally, we share our experience with the prospective surveillance of novel SARS-CoV-2 variants by implementing a two-step laboratory strategy: reverse transcription quantitative real-time polymerase chain reaction PCR (RT-qPCR) screening and whole genome sequencing.

Materials and methods

The Microbiology Department of the Complejo Hospitalario de Navarra, located in Pamplona, the capital city of Navarra (Spain), is the reference laboratory of the public health system for SARS-CoV-2 (approximately 650,000 inhabitants). Upper respiratory specimens for SARS-CoV-2 detection are routinely collected at the hospital and primary care centers, and processed by commercial RT-qPCR methods. Since the end of 2020, when variant B.1.1.7 became predominant in the United Kingdom, prospective sample-based surveillance has been conducted in our community to identify novel emerging SARS-CoV-2 variants. A two-step laboratory procedure included all positive SARS-CoV-2 samples from hospital patients and community settings with a cycle threshold (Ct) less or equal to 30. Occasionally, targeted samples are also included according to epidemiological criteria.

Screening of presumptive SARS-CoV-2 variants carrying Δ H69- Δ V70 deletion was performed using the TaqPathTM COVID-19 RT-PCR kit (Thermo Fisher Scientific, USA) following the manufacturer's instructions. Then, all those samples non-B.1.1.7 variants were subjected to a second RT-qPCR, TaqManTM SARS-CoV-2 Mutation Panel (Thermo Fisher Scientific, USA). At that moment, we customized TaqMan assay for detecting SARS-CoV-2 spike protein with the N501Y, E484K, K417N, K417T mutations. All samples were sequenced.

Whole-genome sequencing was performed using Illumina COVIDSeq Test (Illumina Inc, USA) on the Illumina NovaSeq 6000 located in the public company NASERTIC, following the manufacturer's instructions. The viral lineages classifications were performed by the Global Initiative on Sharing Avian Influenza Data (GISAID) (<https://www.gisaid.org/>) [GISAID EpiCoV] database, Nextstrain (<https://nextstrain.org/>) [Nextstrain] and Phylogenetic Assignment of Named Global Outbreak (PANGO) Lineages (<https://cov-lineages.org/>) [Pango] (8-10).

Results

As of August 1, 2021, a total of 4,728 SARS-COV-2 genomes have been sequenced in Navarra. Our sequencing analysis of the SARS-CoV-2 identified 200 (4.2%) samples related to the B.1.575 lineage: four (2%) B.1.575, two (1%) B.1.575.1 and 194 (97%) B.1.575.2. Among the common substitutions present in these lineages, four occurred in the spike protein (S494P, D614G, P681H, T716I). (11). All samples showed a gene S positive (not carrying Δ H69- Δ V70 deletion) in TaqPath. In TaqMan, all samples identified by sequencing as B.1.575.2 showed the E484K mutation.

The first case with B.1.575 lineage to be identified in Pamplona dates back to January 20, 2021; since that date, no other case was identified until March 15, 2021, where three isolates showing mutations common to the B.1.575 lineage were recorded.

Between weeks 20 to 26 2021, we identified 194 cases with lineage B.1.575, which had acquired another S mutation, E484K, classified in the GISAID EpiCoV and Pangolin databases as the sub-lineage B.1.575.2. The first case with B.1.575.2 lineage was identified in a sample isolated on May 19 (week 20, 2021), and the number of cases grew up to 48 cases in weeks 23 and 24 and declined therefore (Figure 1). The beginning of the outbreak was detected in a car repair shop located in a district of Pamplona. These cases could be related to another more significant outbreak of variant B.1.575.2, which was found in a mosque. Since these first cases, the variant has spread throughout Pamplona and its surroundings without affecting the rest of Navarra. The median age of patients was 33 ± 17 years old, 46.2% women, 53.8% men and approximately 50% Arab origin. Eighty-two (43.1%) patients acquired the infection at domiciliary ambit, the most common cause. Only 14 (7.1%) acquired it at the workplace. One hundred and fifty-six (79.7%) patients showed symptoms, and only four (2.2%) were admitted to hospitals, but none was a severe case. Six (3.3%) of patients have been fully vaccinated for COVID-19 and 35 (19.2%) had received any vaccine dose.

To know the distribution of SARS-CoV-2 B.1.575 lineage, we searched in the GISAID EpiCoV and PANGO lineages databases. From May to July, the lineage and sub-lineages of B.1.575 have increased exponentially in different countries. The B.1.575 lineage was predominant in the United States of America (USA) (90%), while the B.1.575.1 and B.1.575.2 sub-lineages dominated Spain with 86% and 92%, respectively.

The B.1.575.2 sub-lineage was predominant in Navarra since 99.5% (194/197) of the cases registered in the GISAID EpiCoV database were identified in this region. By

contrast, we did not identify any genomes with B.1.575 and B.1.575.1 lineage carrying the E484K mutation.

Conclusions

In this study, we observed the emergence of a lineage B.1.575.2 to acquire the spike E484K mutation circulating in Pamplona associated an outbreak. The new lineage displayed a low prevalence (4.10%) among SARS-CoV-2 genomes analyzed between March 23, 2020, and June 30, 2021. Still, it is already dispersed in our city and comprises 97% of the B.1.575 sequences detected in that period. The E484K mutation is considered one of the most important substitutions associated with reduced antibody neutralization potency and efficacy of the SARS-CoV-2 vaccine (12-14). The E484K mutation has been identified in SARS-CoV-2 variants considered VOC such as B.1.351, P.1 and B.1.1.7+E484K and in VOI variants such as B.1.525, B.1.620, and B1.621 among others (1-3), so the presence of this mutation should be supervised and monitored.

Screening PCR is a useful tool for detecting mutations, mainly because of its rapidity. Future identifications with this method could include new mutations characteristic of the lineage could serve as a rapid method of variant identification. However, whole genome sequencing remains the gold standard technique for pandemic control.

This brief report emphasizes the importance of exhaustive surveillance for circulating variants of the SARS-CoV-2 virus to reduce community transmission and prevent the emergence of more transmissible variants that could further increase the severity of the epidemic in the country.

Conflict of interest

The authors declare no conflict of interest.

Funding

This work was supported by the Horizon 2020 program of the European Commission (I-MOVE-COVID-19, grant agreement No 101003673) and the Carlos III Institute of Health with the European Regional Development Fund (COV20/00542).

Acknowledgements

We would like to thank the GISAID EpiCoV database and all contributing researchers for making the genomes publicly available.

Access to data

All genomes generated in this work were deposited in the GISAID EpiCoV database (<http://gisaid.org>).

Author contributions

CTS, AM, MEP, MFH AN, CE conceived and designed the study. GRO was responsible for the whole genome sequencing interpretation. PSS, PLM, JC provided epidemiology data. CTS wrote the manuscript, and all authors critically revised the manuscript. All authors approved the final version of the manuscript and were accountable for its accuracy.

References

1. CDC: Available from: <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html>. Accessed 30 June 2021.
2. Hirotsu Y, Omata M. 2021. Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan. *PLoS Pathog*;17:e1009619. <http://doi.org/10.1371/journal.ppat.1009619>.
3. Moustafa AM, Bianco C, Denu L, Ahmed A, Neide B, Everett J, Reddy S, Rabut E, Deseignora J, Feldman MD, Rodino KG, Bushman F, Harris RM, Mell JC, Planet PJ. Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2 isolates from Pennsylvania. Preprint. *bioRxiv* 2021;2021.04.440801. <http://doi.org/10.1101/2021.04.21.440801>.
4. European Centre for Disease Prevention and Control. Implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern-23 June 2021. ECDC: Stockholm; 2021.
5. Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, Alford B, Buchser WJ, Ellebedy AH, Fremont DH, Diamond MS, Whelan SPJ. 2021. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *Cell Host Microbe* 29:477–488. <http://doi.org/10.1016/j.chom.2021.01.014>.
6. Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK. 2021. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. *N Engl J Med* 384:1468–1470. <http://doi.org/10.1056/NEJMc2102179>.
7. Public Health England. Investigation of novel SARS-CoV-2 variant: Variant of Concern 202012/01 (Technical briefing 5). 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf.
8. Shu Y, McCauley J. 2017. GISAID: Global initiative on sharing all influenza data from vision to reality. *Euro Surveill* 22:30494. <https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494>.

9. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, Neher RA. 2018. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 34:4121–4123.
<https://doi.org/10.1093/bioinformatics/bty407>.
10. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG. 2020. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol* 5:1403–1407.
<https://doi.org/10.1038/s41564-020-0770-5>.
11. B.1.575 Lineage Report. Alaa Abdel Latif, Julia L. Mullen, Manar Alkuzweny, Ginger Tsueng, Marco Cano, Emily Haag, Jerry Zhou, Mark Zeller, Emory Hufbauer, Nate Matteson, Chunlei Wu, Kristian G. Andersen, Andrew I. Su, Karthik Gangavarapu, Laura D. Hughes, and the Center for Viral Systems Biology. outbreak.info, (available at <https://outbreak.info/situation-reports?pango=b.1.575>). Accessed 30 June 2021.
12. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Personalized Virology Initiative study group, Krammer, F., Simon, V., Martinez-Sobrido, L., García-Sastre, A., Schotsaert, M. 2021. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. *The Lancet. Microbe* 2:e283–e284. [https://doi.org/10.1016/S2666-5247\(21\)00068-9](https://doi.org/10.1016/S2666-5247(21)00068-9).
13. Resende PC, Gräf T, Paixão ACD, Appolinario L, Lopes RS, Mendonça ACDF, da Rocha ASB, Motta FC, Neto LGL, Khouri R, de Oliveira CI, Santos-Muccillo P, Bezerra JF, Teixeira DLF, Riediger I, Debur MDC, Ribeiro-Rodrigues R, Leite AB, do Santos CA, Gregianini TS, Fernandes SB, Bernardes AFL, Cavalcanti AC, Miyajima F, Sachhi C, Mattos T, da Costa CF, Delatorre E, Wallau GL, Naveca FG, Bello G, Siqueira MM.. 2021. A Potential SARS-CoV-2 Variant of Interest (VOI) Harboring Mutation E484K in the Spike Protein Was Identified within Lineage B.1.1.33 Circulating in Brazil. *Viruses* 13:724. <https://doi.org/10.3390/v13050724>.
14. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finklin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z, Abernathy ME, Huey-Tubman KE, Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Da Silva J, Xu J, Colbert RA, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R, Hatzioannou T, Bieniasz PD, Nussenzweig MC. 2021. mRNA vaccine-elicited

226 antibodies to SARS-CoV-2 and circulating variants. *Nature* 592:616–622.
227 <https://doi.org/10.1038/s41586-021-03324-6>.
228

229 **Figure 1.** Timeline of SARS-CoV-2 B.1.575, B1.575.1 and B.1.575.2 lineages
230 emergence in Pamplona between January and June 2021.

Figure 1. Timeline of SARS-CoV-2 B.1.575, B1.575.1 and B.1.575.2 lineages emergence in Pamplona between January and June 2021.